Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

Also called NCT07527078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07527078
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07527078. Randomized; no masking; primary purpose treatment. Start 2026-04-07 (actual); primary completion 2026-04-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
GZR33 Injection
Intervention (Drug)
Insulin Degludec Injection (Tresiba®)
Lead sponsor
Gan & Lee Pharmaceuticals. (class: industry)

Record details

Record id
cardio:ct-nct07527078
Content hash
823b6cd473cd8f83bddc4ba551bf756d559ab8399c9169ce570bf0cb33e6729e